4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines As a New Class of Cytotoxic Hsp90 Inhibitors
Overview
Authors
Affiliations
Hsp90 is considered an interesting therapeutic target for anticancer drug development. Here we describe a new class of 4,5,6,7-tetrahydro-isoxazolo-[4,5-c]-pyridine compounds. A small library of derivatives has been synthesized and investigated. Some reported compounds show interesting properties combining both notable binding to Hsp90 and potent cell growth inhibitory activity. N-5 substitution with a 2,4 resorcinol carboxamide appears crucial for activity. Moreover, a derivative bearing a hydroxamic acid residue bound to C-3 amide portion was found to inhibit both Hsp90 and HDAC6.
Zuccato C, Cosenza L, Tupini C, Finotti A, Sacchetti G, Simoni D Molecules. 2024; 29(1).
PMID: 38202591 PMC: 10779815. DOI: 10.3390/molecules29010008.
Liu P, Xiao J, Wang Y, Song X, Huang L, Ren Z Mol Med. 2021; 27(1):110.
PMID: 34530730 PMC: 8444394. DOI: 10.1186/s10020-021-00375-3.
Lampronti I, Simoni D, Rondanin R, Baruchello R, Scapoli C, Finotti A Oncol Lett. 2020; 20(5):151.
PMID: 32934719 PMC: 7471682. DOI: 10.3892/ol.2020.12002.
The synthetic and therapeutic expedition of isoxazole and its analogs.
Agrawal N, Mishra P Med Chem Res. 2020; 27(5):1309-1344.
PMID: 32214770 PMC: 7079875. DOI: 10.1007/s00044-018-2152-6.